NDA 206321 · Novo
Saxenda
Liraglutide · Subcutaneous · GLP-1 Receptor Agonist
NovelLast checked: Nov 20, 2026Latest source record: Jun 2, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2014
Dec 23, 2014
Approved uses
5
Original approval plus efficacy supplements
Registered trials
434
113 Phase 3, 21 recruiting
FAERS reports
10,421
5,921 serious, 297 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: RISK OF THYROID C-CELL TUMORS • Liraglutide causes dose-dependent and treatment-duration-dependent thyroid C-cell tumors at clinically relevant exposures in both genders of rats and mice. It is unknown whether SAXENDA causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans, as the human relevance of liraglutide-induced rodent thyroid C-cell tumors has not been determined [see Warnings and Precautions ( 5.1 ), Nonclinical Toxicology ( 13.1 )] . • SAXENDA is contraindicated in patients with a personal or family history of MTC and in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Counsel patients regarding the potential risk of MTC with use of SAXENDA and inform them of symptoms of thyroid tumors (e.g., a mass in the neck, dysphagia, dyspnea, persistent hoarseness). Routine monitoring of serum calcitonin or using thyroid ultrasound...
What it is approved for
From the label in effect Feb 25, 2026.
SAXENDA is indicated in combination with a reduced calorie diet and increased physical activity to reduce excess body weight and maintain weight reduction long term in: • Adults and pediatric patients aged 12 years and older with body weight greater than 60 kg and obesity. • Adults with overweight in the presence of at least one weight-related comorbid condition. Limitations of Use • SAXENDA contains liraglutide. Coadministration with other liraglutide-containing products or with any other glucagon-like peptide-1 (GLP-1) receptor agonist is not recommended. • The safety and effectiveness of SAXENDA in pediatric patients with type 2 diabetes have not been established. SAXENDA is a glucagon like peptide 1 (GLP-1) receptor agonist indicated in combination with a reduced calorie diet and increased physical activity to reduce excess body weight and maintain weight reduction long term in: • Adults and pediatric patients aged 12 years and older with body weight greater than 60 kg and obesity. ( 1 ) • Adults with overweight in the presence of at least one weight-related comorbid condition. ( 1 ) Limitations of Use: • Coadministration with other liraglutide-containing products or with any other GLP-1 receptor agonist is not recommended. ( 1 ) • The safety and effectiveness of SAXENDA in pediatric patients with type 2 diabetes have not been established. ( 1 )
Mechanism: Liraglutide is an acylated human GLP-1 receptor agonist with 97% amino acid sequence homology to endogenous human GLP-1(7-37). Like endogenous GLP-1, liraglutide binds to and activates the GLP-1 receptor, a cell-surface receptor coupled to adenylyl cyclase activation through the stimulatory G-protein, Gs. Endogenous GLP-1 has a half-life of 1.5 to 2 minutes due to degradation by the ubiquitous endogenous enzymes, dipeptidyl peptidase 4 (DPP-4) and neutral endopeptidases (NEP). Unlike native GLP-1, liraglutide is stable against metabolic degradation by both peptidases and has a plasma...
Therapeutic areas: Cardiovascular and metabolic
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Dec 4, 2020 Supplement 12 · Efficacy LetterLabel
- Mar 25, 2020 Supplement 11 · Efficacy LabelLetter
- Oct 19, 2018 Supplement 7 · Efficacy LabelLetter
- Apr 26, 2017 Supplement 4 · Efficacy LabelLetterReview
- Dec 23, 2014 Original approval · Type 10 - New Indication Submitted as Distinct NDA - Not Consolidated NovelLabelReviewLetter
1 products under this application
- SAXENDA · LIRAGLUTIDE 18MG/3ML (6MG/ML) · SOLUTION, SUBCUTANEOUS · Prescription · TE AP2
Clinical trials
Interventional ClinicalTrials.gov studies with "Liraglutide" as an intervention, any sponsor and status, largest first.
- Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome ResultsPivotal-lookingCompleted
Novo Nordisk A/SNovo Nordisk (NVO)
NCT01179048 · 9,341 participants · Start Aug 31, 2010 · Primary completion Dec 17, 2015
Drug: liraglutide; placebo · For: Diabetes; Diabetes Mellitus, Type 2
Sites: Alabaster, Alabama; Birmingham, Alabama; Huntsville, Alabama · 428 sites in all
- A Comparative Effectiveness Study of Major Glycemia-lowering Medications for Treatment of Type 2 DiabetesPivotal-lookingCompleted
GRADE Study GroupAcademic, hospital or other
NCT01794143 · 7,850 participants · Start May 2013 · Primary completion Apr 30, 2021
Drug: Sulfonylurea (glimepiride); DPP-4 inhibitor (sitagliptin) and 2 more · For: Type 2 Diabetes; Comparative Effectiveness of Glycemia-lowering Medications
Sites: Birmingham, Alabama; Phoenix, Arizona; San Diego, California · 36 sites in all
- PREvention of CardIovascular and DiabEtic kidNey Disease in Type 2 DiabetesPivotal-lookingRecruiting
Brigham and Women's HospitalAcademic, hospital or other
NCT05390892 · 6,000 participants (planned) · Start Sep 26, 2022 · Primary completion Mar 1, 2029
Drug: SGLT2 inhibitor; GLP-1 receptor agonist · For: Type2Diabetes; ASCVD
Sites: Huntsville, Alabama; Scottsdale, Arizona; Los Angeles, California · 36 sites in all
- Effect of Liraglutide on Body Weight in Non-diabetic Obese Subjects or Overweight Subjects With Co-morbidities: SCALE™ - Obesity and Pre-diabetesPivotal-lookingCompleted
Novo Nordisk A/SNovo Nordisk (NVO)
NCT01272219 · 3,731 participants · Start Jun 1, 2011 · Primary completion Mar 18, 2013
Drug: liraglutide; placebo and 2 more · For: Metabolism and Nutrition Disorder; Obesity
Sites: Birmingham, Alabama; Phoenix, Arizona; Anaheim, California · 226 sites in all
- Efficacy in Controlling Glycaemia With Victoza® (Liraglutide) as add-on to Metformin vs. OADs as add-on to Metformin After up to 104 Weeks of Treatment in Subjects With Type 2 DiabetesPivotal-lookingCompleted
Novo Nordisk A/SNovo Nordisk (NVO)
NCT02730377 · 1,991 participants · Start Mar 28, 2016 · Primary completion Aug 5, 2019
Drug: liraglutide; alpha-glucosidase inhibitors and 5 more · For: Diabetes; Diabetes Mellitus, Type 2
Sites: Birmingham, Alabama; Haleyville, Alabama; Tuscumbia, Alabama · 232 sites in all
- Liraglutide in Acute Minor Ischemic Stroke or High-risk Transient Ischemic Attack Patients With Type 2 Diabetes MellitusPivotal-lookingStatus unknown
First Affiliated Hospital of Jinan UniversityAcademic, hospital or other
NCT03948347 · 1,708 participants (planned) · Start Jun 25, 2019 · Primary completion Dec 2023
Drug: Liraglutide · For: Ischemic Stroke; Transient Ischemic Attack; Type 2 Diabetes Mellitus
Sites: Guangzhou, China
- Dual Action of Liraglutide and Insulin Degludec in Type 2 Diabetes: A Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide, Insulin Degludec and Liraglutide in Subjects With Type 2 DiabetesPivotal-lookingCompleted
Novo Nordisk A/SNovo Nordisk (NVO)
NCT01336023 · 1,663 participants · Start May 23, 2011 · Primary completion May 24, 2012
Drug: insulin degludec/liraglutide; insulin degludec and 1 more · For: Diabetes; Diabetes Mellitus, Type 2
Sites: Birmingham, Alabama; Anaheim, California; Bermuda Dunes, California · 302 sites in all
- The Efficacy and Safety of Liraglutide as Adjunct Therapy to Insulin in the Treatment of Type 1 DiabetesPivotal-lookingCompleted
Novo Nordisk A/SNovo Nordisk (NVO)
NCT01836523 · 1,398 participants · Start Nov 2013 · Primary completion Jun 2015
Drug: liraglutide; placebo and 4 more · For: Diabetes; Diabetes Mellitus, Type 1
Sites: Little Rock, Arkansas; Concord, California; Encino, California · 182 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- nausea1,390
- vomiting809
- diarrhoea566
- drug ineffective546
- off label use518
- weight increased447
- fatigue439
- headache435
- constipation408
- dyspnoea408
- anxiety344
- weight loss poor339
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2008 | 1 |
| 2009 | 2 |
| 2010 | 14 |
| 2011 | 19 |
| 2012 | 30 |
| 2013 | 40 |
| 2014 | 59 |
| 2015 | 359 |
| 2016 | 1,262 |
| 2017 | 1,041 |
| 2018 | 616 |
| 2019 | 805 |
| 2020 | 719 |
| 2021 | 799 |
| 2022 | 814 |
| 2023 | 1,040 |
| 2024 | 863 |
| 2025 | 909 |
| 2026 | 1,029 |
Recalls
1 FDA enforcement reports for this application.
Mar 22, 2021 · Class II · Terminated
Temperature Abuse: product samples were stored at temperatures below 32* F which is not in accordance with storage requirements that could cause a lack of efficacy and damage to the cartridge and pen-injectors.
Shortages
FDA's drug shortage list.
To Be Discontinued · updated Aug 25, 2026
Saxenda, Injection, 6 mg/1 mL (NDC 0169-2800-15). Product will be available until discontinuation in January 2027; Discontinuation of the manufacture of the drug
Current · updated Sep 22, 2026
Saxenda, Injection, 6 mg/1 mL (NDC 0169-2800-15). Discontinuation of the manufacture of the drug
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes.
Marso SP, Daniels GH, Brown-Frandsen K, et al. · N Engl J Med 2016 · Multicenter Study, Randomized Controlled Trial
- Comparison of Clinical Efficacy and Safety of Tirzepatide, Liraglutide and Semaglutide in Patients with Obesity and Without T2D: A Bayesian Network Meta-Analysis of Randomised Controlled Trials.
Ciudin A, Sapin H, Fan L, et al. · Adv Ther 2026 · Network Meta-Analysis, Comparative Study
- Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes: The STEP 8 Randomized Clinical Trial.
Rubino DM, Greenway FL, Khalid U, et al. · JAMA 2022 · Clinical Trial, Phase III, Multicenter Study
- Liraglutide for Children 6 to <12 Years of Age with Obesity - A Randomized Trial.
Fox CK, Barrientos-Pérez M, Bomberg EM, et al. · N Engl J Med 2025 · Randomized Controlled Trial, Clinical Trial, Phase III
- A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management.
Pi-Sunyer X, Astrup A, Fujioka K, et al. · N Engl J Med 2015 · Comparative Study, Multicenter Study
- Healthy Weight Loss Maintenance with Exercise, Liraglutide, or Both Combined.
Lundgren JR, Janus C, Jensen SBK, et al. · N Engl J Med 2021 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
Sponsor: Novo
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.